Eli Lilly and Company
893 S Delaware St
Indianapolis
Indiana
46285
United States
Tel: 317-276-2000
Website: http://www.lilly.com/
About Eli Lilly and Company
Lilly is a global health care leader that unites caring with discovery to make life better for people around the world. For more than a century, we have stayed true to a core set of values – excellence, integrity, and respect for people – that guide us in all we do: discovering medicines that meet real needs, improving the understanding and management of disease, and giving back to communities through philanthropy and volunteerism. We also have been committed to investing in our employees – through competitive salaries, training and development, health, and the opportunity to do good. The pharmaceutical industry is a complex, rapidly changing environment and we’re looking for people who are determined to make life better for people around the world. Visit https://careers.lilly.com for more information.
Stock Symbol: LLY
Stock Exchange: NYSE
We discover life-changing medicines. We commit to diversity and inclusion. We volunteer millions of hours. We make life better. We are Lilly.
2342 articles with Eli Lilly and Company
-
Lilly Launches Open Innovation Challenge to Help Transform Inflammatory Bowel Disease (IBD) Care through Digital Health
8/14/2019
Eli Lilly and Company is launching an open innovation challenge to encourage individuals and teams across the U.S. to identify and submit pioneering digital health solutions aimed at transforming inflammatory bowel disease care.
-
Lilly Announces Superiority of Taltz® (ixekizumab) versus TREMFYA® (guselkumab) in Delivering Total Skin Clearance at Week 12 in Topline Results from Head-to-Head (IXORA-R) Trial in People Living with Moderate to Severe Plaque Psoriasis
8/13/2019
IXORA-R is the first Phase 4 head-to-head study comparing efficacy between an IL-17A inhibitor and an IL-23/p19 inhibitor using PASI 100 as the primary endpoint
-
Patients who took Taltz in the post-marketing study achieved higher rates of “complete skin clearance” in comparison to Tremfya as measured by PASI 100.
-
Clinical Catch-up for August 5-9
8/12/2019
Last week was a particularly busy week for biopharma companies to release information about ongoing clinical trials. Here’s a look. -
U.S. Court of Appeals Rules in Favor of Lilly in Alimta Alternate Salt Form Patent Lawsuit
8/9/2019
Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Court of Appeals for the Federal Circuit ruled in favor of Lilly, confirming that the Alimta® (pemetrexed for injection) vitamin regimen patent would be infringed by competitors that had stated their intent to market alternative salt forms of pemetrexed prior to the patent's expiration in May 2022.
-
BioSpace Movers and Shakers, Aug. 9
8/9/2019
Biopharma companies strengthen their senior leadership teams and boards of directors. -
Lilly, Evidation Health and Apple Study Shows Personal Digital Devices May Help in the Identification of Mild Cognitive Impairment and Mild Alzheimer's Disease Dementia
8/8/2019
Initial results from a feasibility study conducted by Eli Lilly and Company, Evidation Health, and Apple Inc. showed that an iPhone, Apple Watch, iPad and the Beddit sleep monitoring device, in combination with digital apps may be able to differentiate people with mild cognitive impairment and mild Alzheimer's disease dementia.
-
Lilly Announces Positive Results for Emgality (galcanezumab) from the CONQUER Study in Patients who Failed Previous Migraine Preventive Treatments
8/8/2019
Eli Lilly and Company (NYSE: LLY) recently announced that Emgality™ (galcanezumab) met the primary and all key secondary outcomes in CONQUER, a Phase 3 study evaluating the efficacy and safety of Emgality in the preventive treatment of chronic and episodic migraine in patients with documented previous failures on two to four different standard-of-care migraine preventive medication categories
-
Lilly Announces Leadership Changes in Corporate Business Development, Oncology R&D, and Managed Healthcare Services
8/7/2019
Eli Lilly and Company announced several leadership changes in the company's corporate business development, oncology R&D, and managed healthcare services organizations.
-
Lilly Announces Positive Results for Emgality® (galcanezumab-gnlm) from the CONQUER Study in Patients who Failed Previous Migraine Preventive Treatments
8/5/2019
Failure to respond to migraine preventive treatments is a common occurrence; internationally it is estimated that more than 40% of patients who use migraine preventive medications have a history of failure or switching treatments
-
Eli Lilly and Company reported that its Emgality met the primary and all key secondary endpoints in its Phase III CONQUER study for chronic and episodic migraine.
-
Lilly Reports Second-Quarter 2019 Financial Results, Raises 2019 EPS Guidance
7/30/2019
Eli Lilly and Company announced financial results for the second quarter of 2019.
-
Canadians Who Plan For 'lows', Stay On Top Of Their Diabetes!
7/30/2019
New campaign promotes the importance of an individual rescue plan for those…just in case moments!
-
Lilly's Verzenio® (abemaciclib) Significantly Extended Life in Women with HR+, HER2- Advanced Breast Cancer in MONARCH 2
7/30/2019
Verzenio is the first and only CDK4 & 6 inhibitor in combination with fulvestrant to achieve statistically significant improvement in overall survival
-
Major Players Operating in the Esophageal Cancer Drugs Market from 2019 to 2023 | Technavio
7/29/2019
Various combinations of chemotherapy drugs, along with targeted therapy, are necessary for the optimal treatment of esophageal cancer.
-
ON24 Trusted By Life Sciences Companies for Critical Education Needs
7/29/2019
As healthcare evolves for the digital age, the life sciences industry must find innovative ways to educate and stay current with the latest technology.
-
First Patient Dosed in Sintilimab and Anti-VEGF Monoclonal Antibody IBI305 with Chemotherapy in Patients with EGFR-mutant Non-squamous NSCLC who have Progressed from Prior EGFR-TKI Treatment
7/25/2019
Innovent Biologics, Inc. announced that the first patient has been dosed in ORIENT-31, a trial that evaluates Tyvyt®, a fully human anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody co-developed with Eli Lilly and Company, and IBI305, a recombinant humanized anti-vascular endothelial growth factor (anti-VEGF) monoclonal antibody
-
BAQSIMI™ (glucagon) Nasal Powder 3 mg, the First and Only Nasally Administered Glucagon to Treat Severe Hypoglycemia in Adults and Children with Diabetes Ages Four Years and Older, Approved by FDA
7/25/2019
BAQSIMI is expected to be available in U.S. pharmacies within one month
-
It is the first and only nasally-dosed glucagon, which is indicated for diabetic patients undergoing a severe drop in blood sugar. Previously it was only administered by a complicated injection system.
-
The Fortune 500 list is compiled of the 500 U.S.-based companies that generate the most revenue. In the latest ranking, one dozen biopharma companies were included, with one, Johnson & Johnson, breaking into the top 50 and only four in the top 100.